2016-29774. Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs; Correction  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule; correction.

    SUMMARY:

    The Food and Drug Administration (FDA) is correcting a final rule entitled “Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs” that appeared in the Federal Register of August 31, 2016 (81 FR 60169). That final rule amended current regulations Start Printed Page 89849concerning who must register establishments and list human drugs, human drugs that are also biological products, and animal drugs. The final rule was published with an incorrect statement in the preamble about the rule's effect on establishments at which investigational drugs are manufactured. This document corrects that error.

    DATES:

    Effective December 13, 2016.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    David Joy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6254, Silver Spring, MD 20993-0002, 301-796-2242.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In the Federal Register of August 31, 2016 (81 FR 60169), FDA published the final rule “Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs.” The final rule published with an incorrect statement in the preamble about the rule's effect on establishments at which investigational drugs are manufactured. Under the amended regulations, manufacturers, repackers, relabelers, or salvagers who manufacture, repack, relabel, or salvage drugs solely for use in research, teaching, or chemical analysis and not for sale are exempt from the establishment registration requirement under 21 CFR 207.13(e) if they do not engage in other activities that require them to register.

    In the Federal Register of August 31, 2016, in FR Doc. 2016-20471, the following correction is made: On page 60185, in the first column, in the third paragraph under “2. When must initial registration information be provided? (§ 207.21),” the following sentence is removed: “Accordingly, an establishment at which an investigational drug is manufactured is subject to the establishment registration requirement.”

    Start Signature

    Dated: December 7, 2016.

    Leslie Kux,

    Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2016-29774 Filed 12-12-16; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Effective Date:
12/13/2016
Published:
12/13/2016
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule; correction.
Document Number:
2016-29774
Dates:
Effective December 13, 2016.
Pages:
89848-89849 (2 pages)
Docket Numbers:
Docket No. FDA-2005-N-0464 (Formerly Docket No. 2005N-0403)
PDF File:
2016-29774.pdf
Supporting Documents:
» Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Establishment Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution and Blood Establishment Registration and Product Listing
» Tab 5: Cost Impacts of the Over-the-Counter Pharmaceutical Labeling Rule - 03/05/1999 final report
» Tab 3: Draft Final Economic Impact Analysis for a Prospective FDA Rule Governing: Foreign and Domestic Establishment Registration and Listing Requirements for Human Drugs, Certain Biological Drugs, and Animal Drugs - on 08/03/2005
» Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs; Correction
» Ref2_ERG Revisions 1995 DRAFT FINAL REPORT ECONOMIC THRESHOLD AND REGULATORY FLEXIBILITY ASSESSMENT OF PROPOSED CHANGES TO THE CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS FOR MANUFACTURING, PROCESSING, PACKING, OR HOLDING DRUGS (21CFR210&211) re Requi
» Ref1_BLS_wages_May_2014_NAICS325400 - Pharmaceutical and Medicine Manufacturing re Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that are Regulated Under a Biologics License Application, and
» Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that Are Regulated Under a Biologics License Application, and Animal Drugs
» Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs
» Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability
» Guideline re Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability
CFR: (9)
21 CFR 20
21 CFR 201
21 CFR 207
21 CFR 314
21 CFR 514
More ...